Precision Neuroscience Closes $160M Series D to Scale Layer 7 Cortical Interface Platform

Precision Neuroscience has closed a $160 million Series D funding round, the company announced this week, bringing its total capital raised to over $300 million since its founding in 2021. The round was led by SoftBank Vision Fund 2, with participation from existing investors including Steadview Capital, Alumni Ventures, and several undisclosed strategic partners from the medical device sector.

The New York-based company is developing its Layer 7 Cortical Interface, a minimally invasive brain-computer interface that uses a thin-film electrode array inserted through a small cranial slit rather than requiring open-brain surgery. The approach has positioned Precision Neuroscience as a key competitor to Neuralink, though the company has emphasized a regulatory-first, clinician-partnered path to market that has resonated with hospital systems and investors alike.

Chief Executive Officer Benjamin Rapoport said the new capital will be deployed across three primary areas: scaling domestic manufacturing of the electrode arrays, funding a pivotal clinical trial targeting motor restoration in patients with ALS and spinal cord injury, and expanding the company's research partnerships with academic medical centers in the United States and Europe. The company currently holds an IDE from the U.S. Food and Drug Administration for its investigational device and has logged intraoperative data collections at multiple neurosurgery centers.

The round arrives at a moment of intensifying investment activity across the broader neurotech landscape. In the first five months of 2026, venture and growth-stage funding into BCI and neuromodulation companies has already surpassed $900 million globally, according to tracking data from industry analysts, reflecting sustained institutional confidence despite a cautious macroeconomic environment in other deep-tech verticals.

Analysts have pointed to converging factors driving the capital surge: maturing regulatory frameworks for implantable neural devices, growing clinical evidence bases for closed-loop neuromodulation in psychiatric indications, and increasing willingness among large medtech strategics to pursue early-stage partnership arrangements that could lead to acquisition. Medtronic, Abbott, and Boston Scientific have each disclosed exploratory neurotech partnership activities in recent quarters.

For Precision Neuroscience, the pivotal trial timeline remains the central execution challenge. The company has indicated it expects to begin enrolling patients in the motor-restoration study before the end of 2026, with interim data readouts anticipated in 2028. If successful, the data package would support a premarket approval submission targeting a commercial launch in the United States in the 2029 to 2030 timeframe.